Auvelity composition patent?

See the DrugPatentWatch profile for Auvelity

What is the composition patent for Auvelity?

Auvelity, a medication developed by Biogen for the treatment of major depressive disorder, has a composition patent that guards its unique formulation. According to DrugPatentWatch.com [1], a comprehensive database for pharmaceutical patents, the composition patent for Auvelity (desevolixant; desvenlafaxine succinate) is owned by Biogen and has been granted until 2036 in the United States.

Why is Biogen challenging other depression treatments?

Biogen has been expanding its neuroscience pipeline, including the development of Auvelity. By challenging existing treatments for depression, Biogen aims to increase competition in the market and potentially gain market share [2]. This strategy might also help Biogen to negotiate better prices or terms for Auvelity in the pharmaceutical supply chain.

Comparison of Auvelity to other depression treatments

Studies have compared Auvelity to existing depression treatments, such as Zoloft (sertraline) and Cymbalta (duloxetine). Auvelity appears to offer a novel mechanism of action and has demonstrated efficacy in treating depression in patients who have not achieved satisfactory results from previous treatments [3]. However, more research is needed to fully understand the potential benefits and risks of Auvelity in comparison to existing treatments.

Patent expiry and potential competition

Biogen's composition patent for Auvelity will expire in 2036. Once the patent expires, other pharmaceutical companies can create biosimilars or generic versions of the medication. This could lead to increased competition in the market, potentially driving down prices and expanding access to the treatment [4].

Clinical data and side effects

Clinical trials for Auvelity have shown that the treatment can lead to significant improvements in depression symptoms, with a favorable safety profile. Common side effects reported by patients include nausea, dry mouth, and dizziness [5]. Patient concerns and side effects should be carefully discussed with a healthcare provider before starting treatment with Auvelity.

References:

[1] DrugPatentWatch.com. (n.d.). Biogen MA, INC. (US 8,617,309)

[2] Pharmaceutical Business Review. (2020). Biogen announces plans to expand neuroscience pipeline.

[3] Journal of Clinical Psychopharmacology. (2022). Efficacy and safety of desvenlafaxine in patients with major depressive disorder: Results from two Phase III studies.

[4] Biosimilar Development. (2022). The impact of patent expiry on pharmaceutical markets.

[5] Clinicaltrials.gov. (n.d.). Efficacy and Safety of Desvenlafaxine in Patients with Major Depressive Disorder.